Yes, it can be called different things (licensing, collaboration or partnership) but essentially CHM could sell the CLTX rights to a big pharma in exchange for upfront cash, milestone payments and royalties. these are hundreds of millions in upfront cash payments, we are talking about and billions in milestones and royalties.
CHM will still have their licensing agreement with City of Hope, and will need to honor those milestones, which are quite modest given the early stage of this therapy.
In terms of timing, I don’t think it will wait until phase 2 trial results for something to be done. If the phase 1 trial performs as they expect, then this could be partnered up during the phase 1 trial, shortly after the phase 1 trial ends or more likely during the phase 2 trial.
I have done my own research and feel very confident that the demand to partner CLTX will be extremely strong if the phase 1 trial is successful. This is simply based on the fact that every company that has tried to treat GBM has encountered the exact same problem. GBM cancer cells are highly heterogeneous, in that there is no single cell type or antigen to target. It’s all highly diverse, random and able to morph and adapt.
CLTX has a unique ability to bind to a very high percentage of GBM cells as it is not targeting a single antigen (like all other CAR-Ts). So CLTX could possibly be the first of its kind to be able to overcome this obstacle all of these have not been able to.
in other words, where all other CAR-T’s to date were essentially each one type of key trying to unlock solid tumours… CLTX could literally be a master key.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)